These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 22170311)

  • 1. Nonparametric estimation for cumulative duration of adverse events.
    Wang J; Quartey G
    Biom J; 2012 Jan; 54(1):61-74. PubMed ID: 22170311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-parametric inference of adverse events under informative censoring.
    Nishikawa M; Tango T; Ogawa M
    Stat Med; 2006 Dec; 25(23):3981-4003. PubMed ID: 16526008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical methods to analyze adverse events data of randomized clinical trials.
    Siddiqui O
    J Biopharm Stat; 2009 Sep; 19(5):889-99. PubMed ID: 20183450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
    Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
    Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyses of cumulative incidence functions via non-parametric multiple imputation.
    Ruan PK; Gray RJ
    Stat Med; 2008 Nov; 27(27):5709-24. PubMed ID: 18712779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials.
    Sucharew H; Goss CH; Millard SP; Ramsey BW;
    Contemp Clin Trials; 2006 Dec; 27(6):561-70. PubMed ID: 16875884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim monitoring of longitudinal comparative studies with recurrent event responses.
    Cook RJ; Lawless JF
    Biometrics; 1996 Dec; 52(4):1311-23. PubMed ID: 8962455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two commonly used methods for exposure-adverse events analysis: comparisons and evaluations.
    Duan JZ
    J Clin Pharmacol; 2009 May; 49(5):540-52. PubMed ID: 19318526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial.
    Shen Y; Huang X
    Biometrics; 2005 Dec; 61(4):992-9. PubMed ID: 16401272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weighted nonparametric maximum likelihood estimate of a mixing distribution in nonrandomized clinical trials.
    Liu C; Xie J; Zhang Y
    Stat Med; 2007 Dec; 26(29):5303-19. PubMed ID: 17497612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical issues in the analysis of adverse events in time-to-event data.
    Allignol A; Beyersmann J; Schmoor C
    Pharm Stat; 2016 Jul; 15(4):297-305. PubMed ID: 26929180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semiparametric models for cumulative incidence functions.
    Bryant J; Dignam JJ
    Biometrics; 2004 Mar; 60(1):182-90. PubMed ID: 15032788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A regression-based method for estimating mean treatment cost in the presence of right-censoring.
    Carides GW; Heyse JF; Iglewicz B
    Biostatistics; 2000 Sep; 1(3):299-313. PubMed ID: 12933511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some concerns about adverse event reporting in randomized clinical trials.
    Yazici Y
    Bull NYU Hosp Jt Dis; 2008; 66(2):143-5. PubMed ID: 18537786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of adverse events on low back surgery outcome: twenty-four-month follow-up results from a Food And Drug Administration investigational device exemptiontrial.
    Ohnmeiss DD; Bodemer W; Zigler JE
    Spine (Phila Pa 1976); 2010 Apr; 35(7):835-8. PubMed ID: 20195215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
    MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
    Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials.
    Mahoney MR; Sargent DJ; O'Connell MJ; Goldberg RM; Schaefer P; Buckner JC
    J Clin Oncol; 2005 Dec; 23(36):9275-81. PubMed ID: 16361625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pitfalls in meta-analyses on adverse events reported from clinical trials.
    Huang HY; Andrews E; Jones J; Skovron ML; Tilson H
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1014-20. PubMed ID: 21858897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.